Showing results (11-20 of 156) with videos related to
Sort By:
Pageof 16
Cancers|June 27, 2024
Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCCKlara Franke, Susan Foller, Michele Estephania Rosero Moreno, et al.Transplantation Proceedings|February 22, 2021
Rate, Factors, and Outcome of Delayed Graft Function After Kidney Transplantation of Deceased DonorsLaura Jahn, Christiane Rüster, Mandy Schlosser, et al.Clinical Nuclear Medicine|May 5, 2023
67 Ga-PSMA I&T for Radioguided Surgery of Lymph Node Metastases in Patients With Biochemical Recurrence of Prostate CancerThomas Winkens, Frank Peter Berger, Susan Foller, et al.Molecular Cancer|September 14, 2014
Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathwayJulia Roediger, Wiebke Hessenkemper, Sophie Bartsch, et al.European Urology Open Science|October 11, 2021
How to Deal with Renal Cell Carcinoma >7 cm: Radical SurgeryMarc-Oliver Grimm, Katharina LeuchtJournal of Laparoendoscopic & Advanced Surgical Techniques. Part A|December 28, 2021
Factors Affecting Transperitoneal Robot-Assisted Laparoscopic Radical ProstatectomyRoozbeh Tanhaeivash, Marc-Oliver GrimmOncology and Therapy|July 7, 2017
Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 TrialMarc-Oliver Grimm, Viktor GrünwaldOncology Reports|November 6, 2007
An alternatively spliced KAI1 mRNA is expressed at low levels in human bladder cancers and bladder cancer cell lines and is not associated with invasive behaviourPaul Jackson, Alexandra Rowe, Marc-Oliver GrimmDer Urologe. Ausg. A|October 28, 2021
[Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer]K Leucht, S Foller, Marc-Oliver GrimmFuture Oncology (London, England)|January 13, 2018
Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational studyJens Bedke, Marc-Oliver Grimm, Viktor GrünwaldPageof 16